RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and increased the price target from $43 to $53.
February 21, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on IDEAYA Biosciences and raised the price target from $43 to $53.
The increase in price target by a reputable analyst like Gregory Renza suggests a strong bullish outlook on IDEAYA Biosciences. This endorsement is likely to instill confidence in current and potential investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100